Vantive, formerly the Baxter Kidney Care segment, has announced its launch as a new standalone vital organ therapy company following the completion of its acquisition by funds managed by global investment firm Carlyle (NASDAQ: CG) from Baxter International Inc. (NYSE: BAX). This marks a significant step in Vantive’s evolution as an independent entity focused on advancing vital organ therapies.
Background on the Acquisition and Separation
Baxter first revealed its separation plan in January 2023, spinning off its renal care and acute therapies businesses into an independent new company. Vantive will focus on developing and selling products for peritoneal dialysis, hemodialysis, and acute kidney injury treatment in intensive care units. This strategic move aims to enhance the company’s ability to innovate and deliver specialized solutions for patients with critical kidney conditions.
Future Outlook
With the support of Carlyle, Vantive is poised to leverage its expertise in renal care and acute therapies to drive innovation and improve patient outcomes. The company’s independence allows it to focus on developing cutting-edge treatments and technologies, ultimately contributing to the advancement of vital organ therapies globally.-Fineline Info & Tech
